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Gait freezing is an episodic arrest of locomotion due to an inability to take normal steps. Pedunculopontine nucleus stimulation
is an emerging therapy proposed to improve gait freezing, even where refractory to medication. However, the efﬁcacy and
precise effects of pedunculopontine nucleus stimulation on Parkinsonian gait disturbance are not established. The clinical
application of this new therapy is controversial and it is unknown if bilateral stimulation is more effective than unilateral.
Here, in a double-blinded study using objective spatiotemporal gait analysis, we assessed the impact of unilateral and bilateral
pedunculopontine nucleus stimulation on triggered episodes of gait freezing and on background deﬁcits of unconstrained gait in
Parkinson’s disease. Under experimental conditions, while OFF medication, Parkinsonian patients with severe gait freezing
implanted with pedunculopontine nucleus stimulators below the pontomesencephalic junction were assessed during three
conditions; off stimulation, unilateral stimulation and bilateral stimulation. Results were compared to Parkinsonian patients
without gait freezing matched for disease severity and healthy controls. Pedunculopontine nucleus stimulation improved
objective measures of gait freezing, with bilateral stimulation more effective than unilateral. During unconstrained walking,
Parkinsonian patients who experience gait freezing had reduced step length and increased step length variability compared to
patients without gait freezing; however, these deﬁcits were unchanged by pedunculopontine nucleus stimulation. Chronic
pedunculopontine nucleus stimulation improved Freezing of Gait Questionnaire scores, reﬂecting a reduction of the freezing
encountered in patients’ usual environments and medication states. This study provides objective, double-blinded evidence that
in a speciﬁc subgroup of Parkinsonian patients, stimulation of a caudal pedunculopontine nucleus region selectively improves
gait freezing but not background deﬁcits in step length. Bilateral stimulation was more effective than unilateral.
Keywords: Parkinson’s disease; gait freezing; deep brain stimulation; pedunculopontine nucleus
Abbreviations: PD-FOG = patients with Parkinson’s disease with freezing of gait and implanted with bilateral pedunculopontine
nucleus stimulators; UPDRS = Uniﬁed Parkinson’s Disease Rating Scale
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Gait freezing is an episodic arrest of forward progress in
locomotion due to an inability to take normal steps (Giladi and
Nieuwboer, 2008). It is a common, intrusive feature of
Parkinsonian disorders, which causes falls and diminishes quality
of life (Giladi et al., 2001; Moore et al., 2007; Kerr et al., 2010).
Gait freezing is only partially and often poorly responsive to
levodopa and subthalamic nucleus stimulation (Bloem et al.,
2004; Ferraye et al., 2008). Pedunculopontine nucleus stimulation
is proposed to improve gait freezing, even when resistant to
medication (Mazzone et al., 2005; Plaha and Gill, 2005).
However, the precise effects of pedunculopontine nucleus stimu-
lation on Parkinsonian gait disturbance are not yet established
(Peppe et al., 2010). The clinical application of this new treatment
is controversial and basic questions remain regarding patient
selection, targeting and whether bilateral stimulation is better
than unilateral (Stefani et al., 2007; Zrinzo et al., 2007; Ferraye
et al., 2009; Moro et al., 2010; Thevathasan et al., 2011a).
In this double-blinded study, we assessed spatiotemporal
aspects of gait in Parkinsonian patients with severe gait freezing
implanted with pedunculopontine nucleus stimulators and com-
pared results to those of Parkinsonian patients without gait
freezing and healthy controls. We assessed the impact of unilateral
and bilateral pedunculopontine nucleus stimulation on triggered
episodes of gait freezing as well as on background deﬁcits of gait.
Subjects and methods
Subjects and clinical assessments
Three subject groups were assessed: (i) seven patients with Parkinson’s
disease complicated by severe freezing of gait, chronically implanted
with bilateral pedunculopontine nucleus stimulators (PD-FOG group);
(ii) eight patients with Parkinson’s disease of akinetic/rigid subtype
without signiﬁcant gait freezing (Parkinson’s disease control group);
and (iii) nine age-matched healthy controls. For patients in the
PD-FOG group, an inclusion criterion was the presence of clinically
evident gait freezing at baseline during experiments, so that freezing
related deﬁcits could be accurately captured and to avoid the intro-
duction of ﬂoor effects (see Supplementary Material and ‘Discussion’
section). In Parkinson’s disease controls, gait freezing was considered
absent based on a screening history, corroborated by the ‘never freez-
ing’ response on the Freezing of Gait Questionnaire and ﬁnally,
by a lack of clinically evident freezing during experiments.
Parkinson’s disease controls were considered akinetic/rigid in subtype
based on a predominance of bradykinetic features and absent or
only mild tremor, consistent with previous criteria (Selikhova et al.,
2009). Patients with Parkinson’s disease were matched for age, disease
duration, motor severity and cognitive status. Subjects were recruited
from centres in Oxford, England and Brisbane, Australia. Ethics
committee approval was obtained from both centres and participants
gave written informed consent.
Seventeen patients with Parkinson’s disease had received peduncu-
lopontine nucleus stimulators from the study centres at the time of
experiments. Patients with Parkinson’s disease were selected for
pedunculopontine nucleus stimulation because of severe gait freezing
and postural instability persisting even ON medication, causing
frequent falls. The persistence of these deﬁcits despite adequate
dopaminergic medication was determined clinically, including by
examination in a practically deﬁned ON medication state. This was
the dominant symptomatic issue at surgery and motor ﬂuctuations,
if present, were not severe. In Parkinson’s disease, gait freezing
becomes more common and less medication responsive with disease
progression (Giladi et al., 2001; Bloem et al., 2004). The overall
prevalence of gait freezing in Parkinson’s disease is 50% (Macht
et al., 2007). However, severe ON medication gait freezing as the
predominant issue is unusual in Parkinson’s disease (Factor, 2008;
Jankovic, 2008). As there is no deﬁnitive test for Parkinson’s disease
in life, we stress that the diagnosis of Parkinson’s disease in this study
is presumptive.
Of the 17 patients implanted with pedunculopontine nucleus
stimulators at the study centres, six were not recruited due to death
(one patient), living overseas or out of state (two patients), unilateral
stimulation (as analyses employed within-subject comparisons) (one
patient), stimulation still under titration (one patient), deep brain
stimulation system explanted due to therapeutic failure (one patient).
Eleven remaining patients implanted with pedunculopontine nucleus
stimulators were recruited, four of whom were later excluded; two
were unable to perform experimental tasks when OFF medication
(either off or on pedunculopontine nucleus stimulation) due to
severe akinesia and two in whom gait freezing could not be provoked
OFF medication and off stimulation. Of the seven patients in the
PD-FOG group ultimately assessed, clinical outcomes (using unblinded
rating scales) of four and reaction times of six are previously reported
(Thevathasan et al., 2011a, b) Nine control patients with Parkinson’s
disease were recruited and one excluded when freezing unexpectedly
emerged when OFF medication during experiments.
Patients in the PD-FOG group were receiving bilateral stimulation
to the caudal pedunculopontine nucleus region. One patient was
also receiving subthalamic nucleus stimulation (switched off for
experiments). No other patients had received surgery to any other
brain target. Surgical implantation of the pedunculopontine nucleus
from both centres is described previously (Pereira et al., 2008;
Thevathasan et al., 2011a). Figure 1 demonstrates the stimulation
locations (midpoint between active contacts for bipolar stimulation
and cathodes for monopolar). Contacts were identiﬁed on
postoperative computerized tomography fused with preoperative
MRI and transformed onto Montreal Neurological Institute space
using the fMRIB Software Library (Smith et al., 2004). Using local
landmarks as described previously (Ferraye et al., 2009), coordinates
were calculated as follows; laterality from midline (mean 7.1mm,
range 4.6–9mm), ventrodorsal distance (d) from ﬂoor of the fourth
ventricle (mean 5.8mm, range 4.1–7.4mm) and rostro-caudal distance
(h) from a pontomesencephalic line connecting the pontomesencepha-
lic junction to the inferior colliculi caudal margin (mean 5.3mm,
range 2.2 to 8.0mm). In Montreal Neurological Institute space,
the coordinates relative to the anterior commissure for the average
stimulation location, were as follows: X = 7.1mm, Y = 32mm,
Z = 22mm. The relative location/extent of the pedunculopontine
nucleus has been outlined, based on choline-acetyltransferase
immunohistochemical (ChAT5) staining in the human (Mesulam
et al., 1989; Manaye et al., 1999). Stimulation parameters were as
follows: frequency 35Hz (except one patient, 40Hz), voltage range
2.2–4.3V and pulse width 60ms.
Clinical assessments included the motor subsection of the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS, score/108), rated unblinded
by the same neurologist specialized in movement disorders (W.T.) at
both centres. UPDRS was segmented into items 27–30 (IT27/30,
score/16) assessing posture, gait and balance and residual items
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Patients prospectively completed the Gait and Falls Questionnaire
(score/64), which assesses Parkinsonian freezing, festination and falls
(Giladi et al., 2000). The Freezing of Gait Questionnaire (score/24)
and Falls Question (score/4) are components of the Gait and Falls
Questionnaire (Giladi et al., 2000, 2009). These questionnaires were
administered 1day prior to surgery and on the day of experiments
and reﬂected function in patients’ usual environments and medication
states in the preceding weeks. Cognition was assessed with the
Mini-Mental State Examination (score/30).
Clinical details of the study participants are shown in Tables 1 and 2.
PD-FOG, Parkinson’s disease control and healthy control groups were
not signiﬁcantly different in age [F(2,21) = 0.317, P = 0.732]. PD-FOG
and Parkinson’s disease control patients did not differ with respect
to disease duration [t(13) = 0.053, P = 0.958], R-UPDRS subscore
[t(12) = 0.570, P = 0.579] or Mini-Mental State Examination
[t(11) = 0.416, P = 0.686]. Patients in the PD-FOG group had
higher scores in IT27/30 [t(12) = 5.543, P50.001], Gait and
Falls Questionnaire [t(13) = 9.212, P50.001], Freezing of Gait
Questionnaire [t(12) = 10.240, P = 0.001] and Falls Question
[t(12) = 10.223, P50.001].
Experiments
Assessments were performed after overnight withdrawal of dopamin-
ergic medication and after 12h pedunculopontine nucleus stimulation
washout.
PD-FOG patients were assessed during four conditions, presented
in counterbalanced order (using the Latin square method): off pedun-
culopontine nucleus stimulation, bilateral pedunculopontine nucleus
stimulation, left pedunculopontine nucleus stimulation and right ped-
unculopontine nucleus stimulation. Patients were blinded to condition.
The mean of left and right unilateral stimulation results was used
in analyses. Choice of contacts and stimulation parameters were as
Figure 1 Localization of stimulation locations (coloured dots) represented in Montreal Neurological Institute (MNI) space (sagittal and
coronal views). The relative location/extent of the pedunculopontine nucleus has been outlined on the sagittal view, based on choline-
acetyltransferase immunohistochemical (ChAT5) staining in the human. Coordinates were calculated in millimetres from midline (laterality),
ventrodorsal distance (d) from ﬂoor of the fourth ventricle and rostro-caudal distance (h) from a pontomesencephalic line connecting the
pontomesencephalic junction to the inferior colliculi caudal margin, as described previously (Ferraye et al., 2009). The mean (ranges)
of these stimulation site coordinates were as follows: laterality 7.1mm (4.6–9mm), ventrodorsal distance (d) 5.8mm (4.1–7.4mm),
rostro-caudal distance (h) 5.3mm (2.2 to 8.0mm). In Montreal Neurological Institute space, the coordinates relative to the anterior
commissure for the average stimulation location, was as follows; X = 7.1mm, Y = 32mm, Z = 22mm. PM = ponto-mesencephalic line
connecting the pontomesencephalic junction to the caudal end of the inferior colliculi; SC = superior colliculus; IC = inferior colliculus.
Table 1 Baseline characteristics, mean (SD)
Age
(years)
Sex Parkinson’s
disease duration
(years)
MMSE R-UPDRS
OFF
meds/stim
IT27-30
OFF
meds/stim
GFQ FOGQ FallsQ
Healthy controls 67.3 (8.3) 7M, 2F
Parkinson’s
disease controls
64.4 (6.1) 5M, 3F 11.9 (3.4) 29.2 (1.0) 29.4 (9.5) 2.9 (1.6) 3.8 (3.7) 1.9 (1.9) 0.4 (0.7)
PD FOG 66.9 (9.6) 5M, 2F 12.0 (5.5) 28.9 (1.6) 26.7 (8.3) 8.3 (2.1)* 44.9 (12.0)* 19.7 (4.5)* 3.8 (0.4)*
Questionnaire scores for PD FOG patients are preoperative. *Different from Parkinson’s disease controls, P40.001. R-UPDRS = items 1–26 of Uniﬁed Parkinson’s disease
rating scale part III, assessing akinesia, rigidity and tremor (score/92). IT27-30 = items 27–30 of Uniﬁed Parkinson’s disease rating scale part III, assessing gait, posture and
balance (score/16). For all motor scales, higher scores indicate worse function. MMSE = Mini-Mental State Examination (score/30), with lower scores indicating worse
function. For one patient with PD FOG, preoperative FOGQ scores were missing (see Table 2). For Parkinson’s disease controls, UPDRS in one patient and MMSE in two
patients were not tested.
GFQ = Gait and Falls Questionnaire (score/64); FOGQ = Freezing of Gait Questionnaire (score/24); FallsQ = Falls Question (score/4); MMSE = Mini-Mental State
Examination (score/30).
1448 | Brain 2012: 135; 1446–1454 W. Thevathasan et al.employed for chronic therapy. After changing stimulation, a 30-min
wash-in period was enforced between conditions. On questioning at
the conclusion of the wash-in period, patients were unable to detect
the condition of stimulation better than chance.
Data were acquired with an 8.3-m long electronic walkway
(GAITRite, CIR Systems Inc.), which detected footsteps through
embedded pressure sensors (Bilney et al., 2003). GAITRite has been
validated to assess spatiotemporal parameters of gait in health and
Parkinson’s disease (Bilney et al., 2003; Chien et al., 2006).
All participants performed two tasks, presented in counterbalanced
order:
Turn task: this aimed to capture gait freezing, known to be preci-
pitated by turning and tight spaces (Okuma, 2006; Almeida and
Lebold, 2010). Subjects walked to a central marker placed on the
surface two-thirds down the walkway, turned 180 around this
marker and returned to the starting position. In sequential trials,
patients alternately turned left and right. Patients were conﬁned to a
turning arc limited by the width of the electronic walkway (70cm),
which was placed in a narrow corridor 1.4m wide (either pre-existing
or created by a movable screen).
Straight task: this aimed to capture background deﬁcits of gait.
Subjects walked at self-selected speed down the centre of the walk-
way. Distractions were minimized and subjects were requested not to
talk. The walkway was positioned to record established walking and
not gait initiation or slowing down towards destination.
Patients performed four trials per task and the mean result used in
analyses. Trials with falls were discarded and repeated. During experi-
ments, one researcher (W.T.) supervised proceedings, observed for
the presence or absence of gait freezing in patients with Parkinson’s
disease, monitored patient safety (including following discretely behind
patients during trials in case of falls) and altered stimulation. A second,
blinded researcher operated the GAITRite system and tagged the data
according to the order of condition. Ofﬂine, blinded researchers
computed the parameters, including manually deriving the primary
end-points (see below). Conditions of stimulation were then revealed
to permit statistical analysis.
Parameters and data analysis
The primary outcome measure was gait freezing severity as quantiﬁed
by task duration (s) and cadence (steps/min) during turning. Freezing
was not clinically scored during tasks. The turn task parameters were
assessed manually by researchers, blinded to condition, as follows. The
180 arc of the turn was selected for assessment by the appearance
of footsteps at the marker region. Foot-strike was visually identiﬁed,
frame by frame, so that task duration and cadence could be derived
for every trial. This method could not detect any high frequency
attempts at stepping that did not alter foot position as reported
previously in gait freezing (Hausdorff et al., 2003a; Spildooren et al.,
2010). Here cadence pertained to successful stepping and reﬂected
a fundamental feature of gait freezing—a deﬁciency in steps that
alter position (Giladi and Nieuwboer, 2008). Turn task duration was
considered a global measure of functional limitation from freezing
when compared to control subjects. For the straight task, mean
cadence, mean step length and step length standard deviation (SD)
were computed automatically by GAITRite software. Step length
coefﬁcients of variation were then calculated.
Statistics
The Kolmogorov–Smirnov Test demonstrated that parameters during
turning were unlikely to be normally distributed. Log transformed data
of all parameters were normally distributed and used in analyses. Level
of signiﬁcance was P50.05.
Differences between subject groups were assessed with ANOVA
and post hoc independent samples t-tests. Two such ANOVAs were
performed, one with PD-FOG patients off stimulation and one with
PD-FOG patients on bilateral stimulation. In the PD-FOG group, dif-
ferences between stimulation conditions were assessed with repeated
measures ANOVA and post hoc paired t-tests. Post hoc tests were
corrected for multiple comparisons using the False Discovery Rate
Procedure (Bejamini and Hochberg, 1995)
Results
Patients in the PD-FOG group experienced clinically visible gait
freezing episodes only when turning and not during the straight
walking task.
Table 2 Patients in the PD FOG group
Patient Age/sex Parkinson’s
disease
duration
(years)
Post-op
duration
(years,
months)
Levodopa
dose
equivalent
(mg/day)
UPDRS III
OFF/ON
meds
(off stim)
IT27-30
off/on
stim (OFF
meds)
GFQ
pre/
post-op
FOGQ
pre/
post-op
FallsQ
pre/
post-op
Supportive
for UK
brain bank
criteria
a
1 61F 10 2 800 40/23 10/9 61/36 24/16 4/3 D, A, P
2 72M 18 2, 5 2500 25/17 6/6 30/16 14/11 4/2 D, A, T, P
3 76M 6 2 600 26/14 6/4 51/18 22/7 3/3 A, P
4 72F 10 2 950 38/22 11/8 48/26 22/13 4/2 D, A, T, P
5 77M 6 0, 6 1400 31/17 10/10 31/14 ^/6 ^/2 A, P
6 55M 20 1 850 51/19 8/6 38/40 14/15 4/4 D, A, T, P
7 55M 14 0, 2 1650 34/24 7/4 55/37 22/16 4/4 A, P
Postoperative clinical assessments were performed on the same day as gait analysis. Patients 6 and 7 were from Oxford, other patients from Brisbane. Patient 6 also
had subthalamic nucleus stimulators, which were turned off during experiments.
a Additional to disease duration and levodopa response as documented elsewhere in the table. Reaction time data of Patients 1–6 and 2-year clinical scores of Patients
1–4 have been reported previously.
^ = not known; Key to UK Brain bank criteria: D = dyskinesias; A = asymmetry persistent; T = tremor at rest; P = progressive disease course; UPDRS III = part III (motor)
Uniﬁed Parkinson’s disease rating scale (score/108); IT27-30 = items 27–30 of Uniﬁed Parkinson’s disease rating scale, assessing gait, posture and balance (score/16);
GFQ = Gait and Falls Questionnaire (score/64); FOGQ = Freezing of Gait Questionnaire (score/24); FallsQ = Falls Question (score/4).
Parkinsonian gait and pedunculopontine nucleus stimulation Brain 2012: 135; 1446–1454 | 1449Primary outcome: gait freezing during
turning
Turn task duration
Turn task duration (Fig. 2A) differed between PD-FOG patients off
stimulation, Parkinson’s disease controls and healthy subjects
[F(2,21) = 61.213, P50.001]. Post hoc tests revealed that turn
task duration was greater in PD-FOG patients off stimulation
than in Parkinson’s disease controls [mean 31.1s PD-FOG versus
2.7s Parkinson’s disease controls, t(13) = 7.223, P50.001]
and healthy controls [2.3s, t(14) = 7.627, P50.001].
Pedunculopontine nucleus stimulation did not return this measure
to normal, so that turn task duration in PD-FOG patients on
bilateral stimulation (mean 11s), although improved, remained
different to the other subject groups [F(2,21) = 29.066,
P50.001].
In PD-FOG, turn task duration differed between stimulation
conditions [F(1,6) = 16.825, P50.001; Fig. 2A]. Post hoc
tests revealed that compared with off stimulation, turn task
duration reduced with bilateral stimulation [mean 31.1–11.0s,
t(6) = 5.053, P = 0.006] and unilateral stimulation [to 17.5s,
t(6) = 3.068, P = 0.022]. Bilateral stimulation reduced turn task
duration more than unilateral stimulation [t(6) = 3.308,
P = 0.032]. Percentage improvement of turn task duration with
bilateral stimulation was also greater than unilateral stimulation
[57.9 versus 35.5%, t(6) = 2.924, P = 0.026].The impact of unilat-
eral stimulation was not inﬂuenced by the direction of turning
that provoked freezing [19.2s ipsilateral turning versus 14.4s
contralateral turning, t(6) = 0.729, P = 0.494].
Cadence
Cadence during turning differed between PD-FOG patients off
stimulation, Parkinson’s disease controls and healthy subjects
[F(2,21) = 9.885, P = 0.001]. Post hoc tests revealed a deﬁcit
in cadence during turning in PD-FOG patients off stimulation
compared with Parkinson’s disease controls [mean cadence
77.6 steps/min PD-FOG versus 105.9steps/min Parkinson’s
disease controls, t(13) = 3.093, P = 0.032] and healthy controls
[106.1steps/min, t(14) = 3.132, P = 0.032]. With PD-FOG
patients on bilateral stimulation, cadence during turning no
longer differed between subject groups [F(2,21) = 0.126,
P = 0.882].
In PD-FOG, cadence during turning differed between stimula-
tion conditions [F(2,12) = 16.599, P50.001; Fig. 2B]. Post hoc
tests revealed that compared with off stimulation, turning cadence
increased with bilateral stimulation [77.6–110.1steps/min,
t(6) = 4.633, P = 0.012] and unilateral stimulation [to 91.9
steps/min, t(6) = 3.987, P = 0.014]. Bilateral stimulation
increased cadence during turning more than unilateral stimulation
[t(6) = 3.050, P = 0.023]. Percentage improvements of cadence
were also greater with bilateral than unilateral stimulation [47.4
versus 19.7%, t(6) = 2.590, P = 0.041].The impact of unilateral
stimulation on turning cadence was not inﬂuenced by the direction
of turning that provoked freezing [89.4steps/min ipsilateral
Figure 2 Gait analysis parameters (means  SD) recorded when turning in a tight space, a task that precipitated visible gait freezing
in PD-FOG patients but not in Parkinson’s disease controls or healthy controls. Results in PD-FOG patients are grouped according to
stimulation condition: off stimulation, unilateral stimulation and bilateral stimulation. Unilateral stimulation results are the grand averages
of the means of stimulating each side in each patient. (A) Turn task duration (s). (B) Turn task cadence (steps/min). Differences within the
PD-FOG group are indicated by bridges: +P50.01, *P50.05. Compared to the off stimulation state, bilateral stimulation improved
both parameters more than unilateral stimulation. Differences between groups were as follows: (i) turn task duration was longer for
PD-FOG patients during all stimulation conditions than in either control group (P50.001); (ii) turn task cadence was smaller for PD-FOG
patients when off stimulation and with unilateral stimulation than either control group (P50.05) but did not differ between
PD-FOG patients when on bilateral stimulation and control groups (P = 0.882).
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P = 0.270].
Secondary outcomes
Unconstrained walking: straight task parameters
With PD-FOG patients off stimulation, there were signiﬁcant
differences between subject groups in step length [F(2,21) =
31.190, P50.001] and step length coefﬁcient of variation
[F(2,21) = 15.298, P50.001]. Cadence did not differ between
subject groups [F(2,21) = 0.229, P = 0.797]. Post hoc tests
revealed a deﬁcit in step length in the PD-FOG group off
stimulation compared with Parkinson’s disease controls [mean
34.9cm PD-FOG versus 59.8cm Parkinson’s disease controls,
t(13) = 4.987, P = 0.002] and healthy controls [65.5cm,
t(14) = 5.874, P = 0.002]. Step length coefﬁcient of variation
was greater in patients in the PD-FOG group off stimulation
than Parkinson’s disease controls [mean 0.09cm PD-FOG versus
0.03cm Parkinson’s disease controls, t(13) = 3.509, P = 0.004]
and healthy controls [0.02cm, t(14) = 5.947, P = 0.009]. These
group differences remained with patients in the PD-FOG group
on stimulation (Table 3).
In the PD-FOG group, a multivariate ANOVA revealed no
differences between stimulation conditions during the straight
task in step length [F(2,12) = 1.074, P = 0.372], step length coef-
ﬁcient of variation [F(2,12) = 0.215, P = 0.810] or cadence
[F(2,12) = 1.589, P = 0.244].
Falls during recordings
In Parkinson’s disease freezing of gait, falls were recorded in only
one patient when turning; ﬁve times when off stimulation and a
mean of 3.5 times for left and right unilateral stimulation (data
from these trials with falls were discarded and trials repeated).
No falls occurred during bilateral stimulation or in the straight task.
Pre- and postoperative clinical scores
In patients in the PD-FOG group, chronic pedunculopontine
nucleus stimulation improved scores in the Gait and Falls
Questionnaire [44.9 versus 26.7, t(6) = 4.422, P = 0.008] and
Freezing of Gait Question [19.7 versus 13.0, t(5) = 2.988,
P = 0.031] compared with preoperatively (Table 2).
Discussion
Our primary outcome measure was the severity of gait freezing
triggered by turning in a tight space under objective, double-
blinded experimental conditions. Pedunculopontine nucleus
stimulation below the pontomesencephalic junction reduced gait
freezing, with bilateral stimulation more effective than unilateral
stimulation. During unconstrained walking, Parkinsonian patients
who experienced gait freezing had reduced step length and
increased step length variability compared to patients without
gait freezing, but these deﬁcits were unchanged by pedunculo-
pontine nucleus stimulation.
Before further discussion, the validity of our measures to capture
freezing related deﬁcits and quantify freezing needs consideration.
Freezing is notorious for disappearing during single-session assess-
ments, which are therefore prone to underestimating the disorder
(Giladi and Nieuwboer, 2008). For this reason, we assessed
patients OFF medication and employed a strong trigger of freez-
ing; turning in a tight space. Furthermore, we were careful to
include only those PD-FOG patients in whom freezing was clinic-
ally evident in the baseline condition. A limitation is that freezing
was then assessed only with objective spatiotemporal methods and
not also with clinical methods (Giladi et al., 2000). Our turn
task measures aimed to quantify rather than characterize gait
freezing. For example, we could not assess high frequency
attempts at stepping that did not substantially displace the feet
(Spildooren et al., 2010). Rather, we sought to provide objective
measures of functional impairment from gait freezing (turn task
duration) and of stepping that could progress position (turn task
cadence).
This study contributes objective, double-blinded evidence that
pedunculopontine nucleus stimulation can be therapeutic for gait
freezing in Parkinson’s disease. To limit ascertainment bias, we
recruited all 11 patients receiving established bilateral pedunculo-
pontine nucleus stimulation from the study centres living within a
reasonable distance. Of these, two patients could not perform the
tasks due to severe OFF medication akinesia, a deﬁcit that appears
unresponsive to pedunculopontine nucleus stimulation (Moro
et al., 2010). Two patients, apparently successfully treated with
pedunculopontine nucleus stimulation, had persistent remission of
freezing despite having ceased stimulation for 412h. This lack
of freezing could have reﬂected the well described phenomenon
of freezing improving during medical assessments, thought
to result from attentional recruitment (Chee et al., 2009).
Alternatively, the lack of freezing could have reﬂected failure of
stimulation ‘washout’, as studies have suggested that therapeutic
effects may sometimes persist beyond the period of pedunculo-
pontine nucleus stimulation for up to several days (Ostrem et al.,
2010; Thevathasan et al., 2011a). Exclusion of PD-FOG patients
without baseline freezing was necessary for freezing related
deﬁcits to be accurately captured in the baseline condition and
to avoid the introduction of ﬂoor effects, whereby the intervention
(pedunculopontine nucleus stimulation) could not possibly yield
Table 3 Straight task outcomes for the three subject
groups, including patients in the PD-FOG group in all
conditions of stimulation, mean (SD)
Step
length
(cm)
Step
length
CoV (cm)
Cadence
(steps/min)
Healthy controls 65.5 (6.8) 0.02 (0.01) 114.2 (10.6)
Parkinson’s disease
Controls
59.8 (6.3) 0.03 (0.01) 117.0 (6.9)
PD FOG Off DBS 34.9 (9.6)
a 0.09 (0.04)
a 116.9 (12.4)
PD FOG Unilateral DBS 36.1 (8.6)
a 0.09 (0.06)
a 123.6 (9.9)
PD FOG Bilateral DBS 38.7 (7.0)
a 0.09 (0.05)
a 121.5 (13.0)
a PD FOG different to Parkinson’s disease controls and healthy controls, P50.01.
CoV = coefﬁcient of variation; DBS = deep brain stimulation.
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a strategy employed by some studies whereby only treatment
responsive patients are selected for assessment (Leber and Davis,
1998). Although we excluded the two patients who did not
exhibit freezing despite having ceased stimulation for over 12h,
washout effects could still have inﬂuenced our results, persisting
from either chronic therapy or over the 30-min interval, which
could reasonably be provided between conditions. This would
tend to bias towards underestimating the impact of pedunculo-
pontine nucleus stimulation. Furthermore, wash-in effects (e.g.
delays to reach optimal treatment effects) may also have limited
the measured impact of pedunculopontine nucleus stimulation.
Even on bilateral stimulation, PD-FOG patients remained substan-
tially impaired during turning relative to controls. It is not clear if
continuous pedunculopontine nucleus stimulation for 430min
might yield further beneﬁts or if such improvements found
experimentally would enhance quality of life. Such questions call
for a randomized clinical trial.
An important constraint is that the outcomes presented here
reﬂect the speciﬁc selection criteria, target location and stimulation
strategies employed for pedunculopontine nucleus stimulation in
this study, which differ in some respects from previous reports
(Stefani et al., 2007; Ferraye et al., 2009; Moro et al., 2010).
Selected patients were an uncommon subgroup of Parkinson’s
disease who experience extremely severe gait freezing, postural
instability and falls, persisting even ON medication (as established
preoperatively using clinical methods). Severe motor ﬂuctuations
were absent, although these later developed in one patient who
was then implanted with subthalamic nucleus stimulators, which
were switched off for experiments. Thus, our results reﬂect lone
pedunculopontine nucleus stimulation, excluding any interference
from stimulation elsewhere (Ferraye et al., 2011). The relative
efﬁcacy of differing pedunculopontine nucleus stimulation strate-
gies remains to be objectively examined. Stimulation frequencies
employed here (35–40Hz) were intermediate between those
reported as clinically optimal in previous studies, namely
15–25Hz (Stefani et al., 2007; Ferraye et al., 2009) and 60Hz
(Moro et al., 2010). Stimulation was speciﬁcally applied more
caudally in the pedunculopontine nucleus region than previous
reports, beneath the pontomesencephalic junction. This target
was chosen based on the experience of two authors (N.J and
T.Z.A.) in applying pedunculopontine nucleus stimulation in the
non-human primate model of Parkinson’s disease and on the dis-
tribution of cholinergic cells in humans identiﬁed by ChAT5 immu-
nohistochemistry (Olszewski and Baxter, 1954; Mesulam et al.,
1989; Manaye et al., 1999; Nandi et al., 2002; Jenkinson et al.,
2004). Furthermore, at least in animal models, the pedunculopon-
tine nucleus is argued to be topographically organized with the
caudal pedunculopontine nucleus subregion being identiﬁed as
most relevant to locomotor control (Martinez-Gonzalez et al.,
2011). However, the limits of anatomical speciﬁcity from electrical
stimulation must also be acknowledged, particularly in the brain-
stem. In typical subthalamic nucleus stimulation, electrical ﬁelds
are estimated to activate axonal elements up to 4mm from the
active contact (McIntyre et al., 2004). On the one hand, such a
broad ﬁeld of inﬂuence may allow locomotor relevant
pedunculopontine nucleus neurons to be activated despite some
variability in electrode location. Equally, however, the effects of
stimulation in this region could actually result from pedunculopon-
tine nucleus projections or even surrounding nuclei, some of which
are also implicated in locomotor control (Orlovskii et al., 1966;
Zrinzo et al., 2007; Piallat et al., 2009).
The relative efﬁcacy of unilateral versus bilateral pedunculopon-
tine nucleus stimulation has been controversial. Given the state of
equipoise, some have elected to implant unilaterally, given the
greater risks inherent in bilateral implantation (Moro et al.,
2010). However, in an experimental setting, we found that
bilateral pedunculopontine nucleus stimulation improved OFF
medication gait freezing approximately twice as much as unilateral
stimulation (in terms of percentage improvements). We did not
ﬁnd that the effectiveness of unilateral pedunculopontine nucleus
stimulation was inﬂuenced by the direction of turning that trig-
gered freezing. Thus, we cannot explain the greater impact of
bilateral stimulation by a unilateral effect of unilateral stimulation.
During unconstrained walking, patients with Parkinson’s disease
freezing of gait had reduced step length and increased step length
variability compared to well-matched Parkinson’s disease controls
without gait freezing. Thus, these background deﬁcits, unless due
to the pedunculopontine nucleus electrodes or failed stimulation
washout, appear associated with gait freezing and corroborate
ﬁndings from previous studies (Hausdorff et al., 2003b; Chee
et al., 2009; Snijders et al., 2011). Although we did not clinically
observe gait freezing during straight task trials, the abnormalities
of step length could still reﬂect covert freezing interrupting the
smooth execution of gait. Against this, cadence was not abnormal
in PD-FOG patients during straight walking and the step length
deﬁcits did not improve with pedunculopontine nucleus stimula-
tion despite improvements in triggered freezing. The step length
deﬁcits could simply be epiphenomenal to gait freezing. However,
previous studies have found that gait freezing episodes are
commonly preceded by a sequential reduction in step length—a
deﬁcit that would account for the increased step length variability
in our PD-FOG patients (Nieuwboer et al., 2001; Chee et al.,
2009). Furthermore, small steps, deliberately taken, can trigger
freezing (Chee et al., 2009). Step length along with other
manifestations of akinesia, are potentially responsive to levodopa
and subthalamic nucleus stimulation—suggesting a potential
mechanism by which these therapies can improve ‘OFF medication
freezing’ (Faist et al., 2001). However, we found that pedunculo-
pontine nucleus stimulation did not improve step length or its
variability, supporting the proposition that pedunculopontine
nucleus stimulation may improve gait freezing through alternative,
potentially complementary, pathways (Jenkinson et al., 2006;
Thevathasan et al., 2011b).
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